

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit 1614

OKUNO ET AL.

APPLICATION NO: 10/807,736

FILED: MARCH 24, 2004

FOR: USE OF BISPHOSPHONIC ACIDS FOR TREATING
ANGIOGENESIS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER


Sir:

Enclosed herewith is a Terminal Disclaimer in the above-identified application.

The Commissioner is hereby authorized to charge the \$130 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis. An additional copy of this paper is here enclosed.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852
Date: 12/4/07



Oona A. Manzari
Attorney for Applicants
Reg. No. 48,152